Thanks Aiming4. I agree with you, as far as expected news is concerned the approval decision is the only upcoming event that should directly effect the stock price. However, I think that after this correction/downspike has finished, people will start to accumulate these cheap shares again. The recent drop (Feb 26 and on) is not due to the failed clinical trial, but rather just the general market swing, IMO. If the market didnt take the tumble it did, then I would expect that BMRN would have stayed around $18, since it had appeared to stabilize after the BH4/earning results. I am no expert by any means though and I am sure someone with TA skills could be a lot of help in a situation like this. My plan is to wait for the price to stabilize or turn slightly up and then buy some Jan. 2009 call options (LEAPS). I think that would be a fairly safe investment and I expect to take some very nice gains from it. Biomarin is growing to fast for the stock price not to eventually go up. If we see the estimated $25/share this year, I will definitely be one very happy camper, but even if we dont I am going long. The only problem I forsee is the apparently vacant pipeline (besides Phenylase)... but that is a a whole other story. Aiming, do you own BMRN? And what is your outlook on things (BMRN and market in general)?
Thanks,
fearfrost
Market Data 
Markets 
AI
